Effects of Subconjunctival Bevacizumab Injection after Primary Pterygium Surgery
10.3341/jkos.2023.64.8.688
- Author:
Eunyu YOON
1
;
Minji PARK
;
Jaewon CHOI
Author Information
1. Sungmo Eye Hospital, Busan, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2023;64(8):688-693
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:This study evaluated the efficacy and safety of subconjunctival bevacizumab injection after primary pterygium surgery.
Methods:We performed a conjunctivo-limbal autograft after pterygium resection in 136 eyes of 128 patients with primary pterygium between December 2019 and July 2021. A subconjunctival bevacizumab injection of 2.5 mg (0.1 mL) was administered in the bevacizumab group but not in the control group (54 eyes of 48 patients). We compared pterygium recurrence rates between the two groups at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery.
Results:Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed.
Conclusions:Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed.
